RiverVest is a leading venture capital firm building life science companies
to address significant unmet needs of patients and deliver consistently strong returns to investors.
Avalyn Raises $175 Million in Oversubscribed Series C Financing to Advance Inhaled Pulmonary Fibrosis Programs into Later Stage Clinical Studies – 9/27/2023
Mirum Pharmaceuticals Completes Acquisition of Bile Acid Product Portfolio for Treatment of Rare Liver Diseases from Travere Therapeutics – 9/5/2023
Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2023 Financial Results 8/14/2023
Reneo Pharmaceuticals Reports Second Quarter 2023 Financial Results 8/10/2023
Allakos provides Business Update and Reports Second Quarter 2023 Financial Results 8/9/2023
Mirum Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update 8/3/2023
Mirum Pharmaceuticals Enters Agreement to Acquire Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases from Travere Therapeutics 7/17/2023
Biolinq and Taisho Pharmaceutical Announce Strategic Collaboration and Exclusive License Agreement in Japan 6/20/2023
Wugen Presents Initial Data from First-in-Human Phase 1/2 Trial of WU-CART-007 at European Hematology Association (EHA) 2023 Congress 6/9/2023
Bluejay Therapeutics Advances in Hepatitis B and D Trials: Successfully Completes BJT-778 Phase 1a Study and Begins Phase 1b Trial Enrollment 6/1/2023
Xilio Therapeutics Announces Preliminary Clinical Data from Phase 1 Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Patients with Advanced Solid Tumors 5/25/2023
OncoResponse Awarded $13 Million in Funding from CPRIT and Raises $14 Million in Added Funds from Investors to Advance Cancer Immunotherapy 5/18/2023
Reports First Quarter 2023 Financial Results and Provides Corporate Updates – 5/15/2023
Reneo Pharmaceuticals Reports First Quarter 2023 Financial Results 5/11/2023
Wugen Appoints Industry Leader Mark Alles as Chair of the Board of Directors – 5/10/2023
Provides Business Update and Reports First Quarter 2023 Financial Results – 5/9/2023
Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2023 Financial Results – 5/9/2023
Mirum Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update – 5/4/2023
Reneo Pharmaceuticals Announces Proposed Public Offering of Common Stock – 5/3/2023
Avalyn Pharma Reports Data After One Year of Treatment in Ongoing AP01 Open-label Extension Trial in Adults with Pulmonary Fibrosis– 4/11/2023
Industry Leader Tim Walbert Joins Mirum Pharmaceuticals’ Board of Directors– 4/6/2023
Publishes Phase 1b ATLAS Results Demonstrating Stabilization of Lung Function at 24 and 48 Weeks with AP01 and Favorable Safety Profile – 3/23/2023
Wugen, Inc. Announces CEO Transition — Kumar Srinivasan Ph.D., M.B.A., Appointed President and Chief Executive Officer – 3/21/2023
Reneo Pharmaceuticals Achieves Target Enrollment in the Pivotal STRIDE Study of Mavodelpar (REN001) in Primary Mitochondrial Myopathies – 3/14/2023
Mirum Pharmaceuticals Announces Label Expansion for LIVMARLI in the United States to Include Infants Three Months of Age and Older- 3/14/2023
Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results – 3/6/2023
Mirum Pharmaceuticals Submits Supplemental New Drug Application to FDA for LIVMARLI in Patients with Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis – 2/14/2023
Spruce Biosciences Announces $53.6 Million Private Placement Financing – 2/9/2023
Reneo Pharmaceuticals Receives Fast Track Designation from the FDA for Mavodelpar (REN001) in a Genotype of Long-Chain Fatty Acid Oxidation Disorder (LC-FAOD) – 1/31/2023
Alleviant Medical Closes $75M in Financing; Receives FDA IDE Approval for Pivotal Clinical Trial – 1/26/2023
Glycomine Announces First Patient Dosed in Phase 2 Clinical Study of GLM101, a Potential Treatment for PMM2-CDG – 1/9/2023
Spruce Biosciences and Karen Pharmaceutical Announce Strategic Partnership and Exclusive Licensing Agreement to Develop and Commercialize Tildacerfont for CAH in Japan – 1/5/2023
Mirum Pharmaceuticals‘ LIV MARLI (maralixibat) Approved by the European Commission for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome Two Months and Older – 12/13/2022
Mirum Pharmaceuticals Enters Agreement to Acquire Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases from Travere Therapeutics 7/17/2023
Subscribe to our newsletter